Rebranding to Cerenome marks a strategic shift to an integrated CNS oncology platform, with key 2026 objectives for therapeutics and diagnostics divisions on track. AI initiatives are expected to drive operational efficiency and data-driven value, while payer coverage and test adoption for CNSide are accelerating.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.